{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:13:11Z","timestamp":1788340391828,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstracts<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell immunotherapy has achieved remarkable success in hematologic malignancies, prompting the exploration of CAR strategies in solid tumors. Here, we developed a CAR-like signal-switching receptor-macrophage (SR CAR-M) that recognizes IL-10, a major immunosuppressive cytokine enriched in solid tumors, and converts this inhibitory signal into a pro-inflammatory activation through the Toll-like receptor 9 (TLR9) intracellular signaling pathway. SR CAR-Ms effectively blocked IL-10-mediated STAT3 phosphorylation while activating TLR9 downstream signaling, including nuclear translocation of nuclear factor-\u03baB and upregulation of IRF1, thereby adopting an M1-like phenotype with enhanced phagocytic capacity and tumor cytotoxicity. Domain-deletion controls demonstrated that both IL-10 binding and TLR9 signaling are indispensable. In addition, SR CAR-Ms promoted dendritic cell maturation, enhanced T cell proliferation and effector function, and prevented T cell exhaustion. In an orthotopic 4T1 breast cancer model, infused SR CAR-Ms selectively accumulated in tumors, depleted local IL-10 while inducing inflammatory cytokine production, suppressed tumor growth, and prolonged survival without systemic toxicity. The signal-switching mechanism was validated in primary bone marrow-derived macrophages and human monocyte-derived macrophages, supporting the translational applicability. Further enhancement was achieved by engineering dual-function SRP\u03b1 CAR-Ms secreting anti-PD-L1 antibodies, which outperformed either SR CAR-M or anti-PD-L1 monotherapy. The SR CAR-M platform transforms an immunosuppressive cytokine into a location-specific activation trigger, simultaneously depleting the inhibitory signal and remodeling the tumor microenvironment. This signal-switching paradigm offers a versatile approach for treating solid malignancies that are resistant to conventional immunotherapies.<\/jats:p>","DOI":"10.1038\/s12276-026-01800-5","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:51:55Z","timestamp":1785999115000},"page":"2701-2718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineered macrophages with IL-10\u2013TLR9 signal switch receptors for reprogramming tumor microenvironment and enhancing antitumor immunity"],"prefix":"10.1038","volume":"58","author":[{"given":"Sijie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owais","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"1800_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665\u2013679 (2025).","journal-title":"Cancer Cell"},{"key":"1800_CR2","doi-asserted-by":"publisher","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2025","unstructured":"Kong, Y., Li, J., Zhao, X., Wu, Y. & Chen, L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol. 15, 1519671 (2025).","journal-title":"Front Immunol."},{"key":"1800_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai, K. et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol 17, 105 (2024).","journal-title":"J Hematol Oncol"},{"key":"1800_CR4","doi-asserted-by":"publisher","first-page":"1489827","DOI":"10.3389\/fimmu.2024.1489827","volume":"15","author":"SH Khan","year":"2025","unstructured":"Khan, S. H., Choi, Y., Veena, M., Lee, J. K. & Shin, D. S. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. Front Immunol 15, 1489827 (2025).","journal-title":"Front Immunol"},{"key":"1800_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen, T., Wang, M., Chen, Y. & Liu, Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int 24, 133 (2024).","journal-title":"Cancer Cell Int"},{"key":"1800_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","volume":"17","author":"H Huang","year":"2024","unstructured":"Huang, H. et al. Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. J Hematol Oncol. 17, 120 (2024).","journal-title":"J Hematol Oncol."},{"key":"1800_CR7","first-page":"96","volume":"52","author":"LT Tony","year":"2025","unstructured":"Tony, L. T., Stabile, A., Schauer, M. P., Hudecek, M. & Weber, J. CAR-T cell therapy for solid tumors. Transfus. Med. Hemother. 52, 96\u2013108 (2025).","journal-title":"Transfus. Med. Hemother."},{"key":"1800_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu, J. et al. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 12, 86 (2024).","journal-title":"Biomark Res."},{"key":"1800_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.17305\/bb.2023.9675","volume":"24","author":"K Chen","year":"2024","unstructured":"Chen, K., Liu, M.-L., Wang, J.-C. & Fang, S. CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar. Biomol Biomed 24, 465\u2013476 (2024).","journal-title":"Biomol Biomed"},{"key":"1800_CR10","doi-asserted-by":"publisher","first-page":"1464218","DOI":"10.3389\/fcell.2024.1464218","volume":"12","author":"T Huang","year":"2024","unstructured":"Huang, T., Bei, C., Hu, Z. & Li, Y. CAR-macrophage: breaking new ground in cellular immunotherapy. Front Cell Dev Biol. 12, 1464218 (2024).","journal-title":"Front Cell Dev Biol."},{"key":"1800_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 31, 1171\u20131182 (2025).","journal-title":"Nat Med."},{"key":"1800_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li, N. et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer 23, 117 (2024).","journal-title":"Mol Cancer"},{"key":"1800_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 44, 145 (2025).","journal-title":"J Exp Clin Cancer Res."},{"key":"1800_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li, J., Chen, P. & Ma, W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 13, 76 (2024).","journal-title":"Exp Hematol Oncol."},{"key":"1800_CR15","doi-asserted-by":"publisher","first-page":"e0298465","DOI":"10.1371\/journal.pone.0298465","volume":"19","author":"L Volk-Draper","year":"2024","unstructured":"Volk-Draper, L. et al. Tumor microenvironment restricts IL-10 induced multipotent progenitors to myeloid-lymphatic phenotype. PLoS ONE 19, e0298465 (2024).","journal-title":"PLoS ONE"},{"key":"1800_CR16","doi-asserted-by":"publisher","first-page":"1497522","DOI":"10.3389\/fimmu.2024.1497522","volume":"15","author":"M Bida","year":"2024","unstructured":"Bida, M., Miya, T. V., Hull, R. & Dlamini, Z. Tumor-infi ltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications. Front. Immunol. 15, 1497522 (2024).","journal-title":"Front. Immunol."},{"key":"1800_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003416","volume":"10","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer 10, e003416 (2022).","journal-title":"J Immunother Cancer"},{"key":"1800_CR18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","volume":"80","author":"AM Shiri","year":"2024","unstructured":"Shiri, A. M. et al. IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction. J Hepatol 80, 634\u2013644 (2024).","journal-title":"J Hepatol"},{"key":"1800_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun. 13, 925 (2022).","journal-title":"Nat Commun"},{"key":"1800_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55593-6","volume":"14","author":"SK Daniel","year":"2024","unstructured":"Daniel, S. K. et al. Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade. Sci Rep. 14, 5109 (2024).","journal-title":"Sci Rep"},{"key":"1800_CR21","doi-asserted-by":"publisher","first-page":"1662238","DOI":"10.3389\/fimmu.2025.1662238","volume":"16","author":"R Rane","year":"2025","unstructured":"Rane, R. et al. Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment. Front. Immunol. 16, 1662238 (2025).","journal-title":"Front. Immunol."},{"key":"1800_CR22","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1158\/1078-0432.CCR-23-1160","volume":"30","author":"Z Ren","year":"2024","unstructured":"Ren, Z., Zhang, X. & Fu, Y.-X. Facts and hopes on chimeric cytokine agents for cancer immunotherapy. Clin Cancer Res. 30, 2025\u20132038 (2024).","journal-title":"Clin Cancer Res."},{"key":"1800_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther 25, 249\u2013258 (2017).","journal-title":"Mol Ther"},{"key":"1800_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxad033","volume":"36","author":"Y Kagoya","year":"2023","unstructured":"Kagoya, Y. Cytokine signaling in chimeric antigen receptor T-cell therapy. Int Immunol 36, 49\u201356 (2023).","journal-title":"Int Immunol"},{"key":"1800_CR25","doi-asserted-by":"publisher","first-page":"1460266","DOI":"10.3389\/fimmu.2024.1460266","volume":"15","author":"T Matikhina","year":"2024","unstructured":"Matikhina, T. & Cohen, C. J. Targeting TGF\u03b2 with chimeric switch receptor and secreted trap to improve T cells anti-tumor activity. Front Immunol. 15, 1460266 (2024).","journal-title":"Front Immunol."},{"key":"1800_CR26","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1158\/2326-6066.CIR-23-0823","volume":"12","author":"V Eisenberg","year":"2024","unstructured":"Eisenberg, V. et al. Targeting tumor-associated sialic acids using chimeric switch receptors based on Siglec-9 enhances the antitumor efficacy of engineered T cells. Cancer Immunol Res. 12, 1380\u20131391 (2024).","journal-title":"Cancer Immunol Res."},{"key":"1800_CR27","doi-asserted-by":"publisher","first-page":"101526","DOI":"10.1016\/j.xcrm.2024.101526","volume":"5","author":"T Yoshikawa","year":"2024","unstructured":"Yoshikawa, T. et al. Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell Rep Med. 5, 101526 (2024).","journal-title":"Cell Rep Med."},{"key":"1800_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41551-025-01387-8","volume":"9","author":"Q Cao","year":"2025","unstructured":"Cao, Q. et al. Targeting inflammation with chimeric antigen receptor macrophages using a signal switch. Nat Biomed Eng. 9, 1502\u20131516 (2025).","journal-title":"Nat Biomed Eng."},{"key":"1800_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00523-6","volume":"8","author":"Z Niu","year":"2017","unstructured":"Niu, Z. et al. Caspase-1 cleaves PPAR\u03b3 for potentiating the pro-tumor action of TAMs. Nat Commun. 8, 766 (2017).","journal-title":"Nat Commun."},{"key":"1800_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","volume":"51","author":"T Sato","year":"2011","unstructured":"Sato, T. et al. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 51, 170\u2013182 (2011).","journal-title":"Immunol Res."},{"key":"1800_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni, M. A. & Naing, A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9, 716\u2013725 (2023).","journal-title":"Trends Cancer"},{"key":"1800_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","volume":"2","author":"M Oft","year":"2014","unstructured":"Oft, M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2, 194\u2013199 (2014).","journal-title":"Cancer Immunol Res."},{"key":"1800_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/35047123","volume":"408","author":"H Hemmi","year":"2000","unstructured":"Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740\u2013745 (2000).","journal-title":"Nature"},{"key":"1800_CR34","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044\u20131066 (2020).","journal-title":"Cell"},{"key":"1800_CR35","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117\u20131134 (2010).","journal-title":"Cell"},{"key":"1800_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 11, 373\u2013384 (2010).","journal-title":"Nat Immunol."},{"key":"1800_CR37","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1172\/JCI31414","volume":"117","author":"AM Krieg","year":"2007","unstructured":"Krieg, A. M. Development of TLR9 agonists for cancer therapy. J Clin Investig 117, 1184\u20131194 (2007).","journal-title":"J Clin Investig"},{"key":"1800_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cimb47020090","volume":"47","author":"T-H Jaing","year":"2025","unstructured":"Jaing, T.-H., Hsiao, Y.-W. & Wang, Y.-L. Chimeric antigen receptor cell therapy: empowering treatment strategies for solid tumors. Curr Issues Mol Biol. 47, 90 (2025).","journal-title":"Curr Issues Mol Biol."},{"key":"1800_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/INMD.20230047","volume":"2","author":"K Qian","year":"2024","unstructured":"Qian, K. et al. CAR-T-cell products in solid tumors: progress, challenges, and strategies. Interdiscip Med 2, e20230047 (2024).","journal-title":"Interdiscip Med"},{"key":"1800_CR40","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta, L. & Pollard, J. W. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 17, 887\u2013904 (2018).","journal-title":"Nat Rev Drug Discov."},{"key":"1800_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.830208","volume":"10","author":"K Park","year":"2022","unstructured":"Park, K., Veena, M. S. & Shin, D. S. Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies. Front Cell Dev Biol. 10, 830208 (2022).","journal-title":"Front Cell Dev Biol."},{"key":"1800_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm, J. B. et al. IL-10 elicits IFN\u03b3-dependent tumor immune surveillance. Cancer Cell 20, 781\u2013796 (2011).","journal-title":"Cancer Cell"},{"key":"1800_CR43","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"A Naing","year":"2018","unstructured":"Naing, A. et al. PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell 34, 775\u2013791.e3 (2018).","journal-title":"Cancer Cell"},{"key":"1800_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin, H. et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 18, 62 (2025).","journal-title":"J Hematol Oncol."},{"key":"1800_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva, M. & O\u2019Garra, A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 10, 170\u2013181 (2010).","journal-title":"Nat Rev Immunol."},{"key":"1800_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu, L., Xie, M., Yang, B., Zhao, W. B. & Cao, J. Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control. Sci Adv 10, eadj6251 (2024).","journal-title":"Sci Adv"},{"key":"1800_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41590-023-01696-7","volume":"25","author":"SM Abdin","year":"2024","unstructured":"Abdin, S. M., Paasch, D. & Lachmann, N. CAR macrophages on a fast track to solid tumor therapy. Nat Immunol. 25, 11\u201312 (2024).","journal-title":"Nat Immunol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01800-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01800-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01800-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:14:36Z","timestamp":1788336876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01800-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1800"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01800-5","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experimental procedures were approved by the Institutional Animal Care and Use Committee of Nanjing University (IACUC-2210008).","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}